Table 2 Uni- and multivariate analysis in locally advanced rectal adenocarcinoma patients
Univariate | Multivariate | |||
|---|---|---|---|---|
Variable | OR (95 % CI) | p value | OR (95 % CI) | p value |
Age (continuous) | 1.03 (0.99–1.10) | 0.145 | ||
Gender (categorical) | 0.544 | |||
Male | Reference | |||
Female | 0.72 (0.25–2.10) | |||
ECOG performance status (categorical) | ||||
0 | Reference | 0.802 | ||
≥ 1 | 0.87 (0.31–2.40) | |||
Tumor invasion depth (categorical) | ||||
T1-T2 | Reference | 0.836 | ||
T3-T4 | 0.85 (0.20 – 3.70) | |||
Lymph node metastases (categorical) | ||||
N0 | Reference | 0.152 | ||
N+ | 0.31 (0.06 – 1.54) | |||
Grade of differentiation (categorical) | ||||
Low grade | Reference | 0.465 | ||
Moderate-High grade | 0.64 (0.19–2.13) | |||
LVI (categorical) | ||||
No | Reference | 0.108 | ||
Yes | 0.23 (0.04–1.38) | |||
Neoadjuvant chemoradiotherapy (categorical) | ||||
RDT- Flouropyrimidines | Reference | 0.260 | ||
RDT- Flouropyrimidines - Oxaliplatin | 0.49 (0.14–1.70) | |||
Tumor size (continuous) | 0.65 (0.46–0.90) | 0.011 | 0.65 (0.45–0.94) | 0.021 |
Anal verge distance (continuous) | 0.96 (0.82–1.12) | 0.610 | ||
VRK1 HSCORE (continuous) | 1.20 (1.01–1.43) | 0.033 | ||
VRK2 HSCORE (continuous) | 1.23 (1.03–1.50) | 0.023 | ||
COMPOSITE SCORE (continuous) | 1.24 (1.07–1.44) | 0.004 | 1.24 (1.07–1.48) | 0.005 |